NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and
Expands Stem Cell Collection Network into New Jersey
NEW YORK, May 6 /PRNewswire-AsiaNet/ --
NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease
collection, processing and long-term storage of adult stem cells for future
medical need, has filed a patent application claiming the proprietary stem
cell technology of Vincent C. Giampapa, M.D., F.A.C.S. relating to cosmetic
facial rejuvenation, which NeoStem first licensed in February 2009.
The newest adult stem cell collection center in the NeoStem network,
located at the Giampapa Institute for Anti-Aging Medical Therapy in
Montclair, New Jersey, has received, from the state of New Jersey Department
of Health and Senior Services, a blood bank license for autologous peripheral
blood stem cell collection. This allows the center to open and commence
operations, and together with the patent application will serve to
significantly advance NeoStem's leadership in the anti-aging and regenerative
medicine arena.
Dr. Giampapa, director of the Giampapa Institute for Anti-Aging Medical
Therapy, is a board-certified plastic reconstructive surgeon and Assistant
Clinical Professor of Plastic and Reconstructive Surgery at the University of
Medicine and Dentistry of New Jersey and is one of the first certified
anti-aging medical physicians in the world. His research and technology
comprise a non-surgical procedure for complete facial rejuvenation that
involves injecting pluripotent cells, including stem cells, into the skin of
individuals whose skin has lost its firmness and texture due to age. The
pluripotent cells stimulate the growth of various cells in the skin, leading
to the restoration of the skin's firmness and texture. The procedure can be
accomplished under local anesthesia in an office setting and typically
requires only a week of recovery time.
"NeoStem is very focused on acquiring technologies related to stem cell
therapies," stated Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer.
"We are especially delighted to strengthen our relationship with Dr.
Giampapa, as anti-aging technology is one of our key pursuits. Filing a
patent for stem cell facial rejuvenation technology, while launching a new
NeoStem collection center at the Giampapa Institute, creates a particularly
advantageous situation for NeoStem. Just last week, the Food and Drug
Administration announced that Botox and similar anti-wrinkle drugs must now
carry "black box" warning labels explaining the potential of these materials
to spread from the injection site to distant parts of the body, creating
possible problems with swallowing or breathing. People worldwide can be
expected to seek safer alternatives and NeoStem believes that the use of
autologous stem cell procedures ("Your Cells for Your Use") may in fact be
that effective, safe and non-invasive alternative."
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers
that are focused on enabling people to donate and store their own
(autologous) stem cells when they are young and healthy for their personal
use in times of future medical need. The Company has also entered into
research and development through the acquisition of a worldwide exclusive
license to technology to identify and isolate VSELs (very small
embryonic-like stem cells), which have been shown to have several physical
characteristics that are generally found in embryonic stem cells. The Company
is also pursuing other technologies to advance it position in the field of
stem cell tissue regeneration.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. The Company's
actual results, including the success of the collection centers in its
network and whether the patent application described in this press release
will issue, could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could
cause future results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors" described
in the Company's Annual Report on Form 10-K for its fiscal year ended
December 31, 2008 and the Company's other periodic filings with the
Securities and Exchange Commission. The Company's further development is
highly dependent on future medical and research developments and market
acceptance, which is outside its control.
Contact:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com
SOURCE: NeoStem, Inc.
CONTACT: Robin Smith
Chief Executive Officer of NeoStem, Inc.
+1-212-584-4180
rsmith@neostem.com
(NBS)
Translations:
NEWS 
